Skip Nav Destination
Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib
Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL
Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms
Antirelapse effect of pretransplant exposure to rabbit antithymocyte globulin
GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia
Issue Archive
Table of Contents
CLINICAL TRIALS AND OBSERVATIONS
Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma
Clinical Trials & Observations
Chelsea C. Pinnix,Sarah A. Milgrom,Chan Yoon Cheah,Jillian R. Gunther,Ethan B. Ludmir,Christine F. Wogan,Loretta J. Nastoupil,Sattva S. Neelapu,Jason Westin,Hun J. Lee,Swaminathan P. Iyer,Raphael E. Steiner,Luis E. Fayad,Nathan H. Fowler,Michael L. Wang,Felipe Samaniego,Maria A. Rodriguez,Amy E. Rich,L. Jeffrey Medeiros,Bouthaina S. Dabaja
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib
Clinical Trials & Observations
Farrukh T. Awan,Anna Schuh,Jennifer R. Brown,Richard R. Furman,John M. Pagel,Peter Hillmen,Deborah M. Stephens,Jennifer Woyach,Elena Bibikova,Prista Charuworn,Melanie M. Frigault,Ahmed Hamdy,Raquel Izumi,Bolan Linghu,Priti Patel,Min Hui Wang,John C. Byrd
The introduction of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib revolutionized the treatment of chronic lymphocytic leukemia. However, because inefficacy or intolerable side effects, some patients do not benefit. Acalabrutinib is a covalent BTK inhibitor with greater selectivity than ibrutinib. Byrd and colleagues explored acalabrutinib in patients refractory to or intolerant of ibrutinib, finding exciting evidence for efficacy and tolerability.
LYMPHOID NEOPLASIA
Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL
Clinical Trials & Observations
Paolo Strati,Koichi Takahashi,Christine B. Peterson,Michael J. Keating,Philip A. Thompson,Naval G. Daver,Nitin Jain,Jan A. Burger,Zeev Estrov,Susan M. O'Brien,Hagop M. Kantarjian,William G. Wierda,P. Andrew Futreal,Alessandra Ferrajoli
MYELOID NEOPLASIA
Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms
Clinical Trials & Observations
Sanjay S. Patel,Caleb Ho,Ryan N. Ptashkin,Sam Sadigh,Adam Bagg,Julia T. Geyer,Mina L. Xu,Thomas Prebet,Emily F. Mason,Adam C. Seegmiller,Elizabeth A. Morgan,David P. Steensma,Eric S. Winer,Waihay J. Wong,Robert P. Hasserjian,Olga K. Weinberg
PLATELETS AND THROMBOPOIESIS
Dysregulated megakaryocyte distribution associated with nestin+ mesenchymal stem cells in immune thrombocytopenia
Min Wang,Ru Feng,Jia-min Zhang,Lin-lin Xu,Fei-er Feng,Chen-cong Wang,Qian-ming Wang,Xiao-lu Zhu,Yun He,Jing Xue,Hai-xia Fu,Meng Lv,Yuan Kong,Ying-jun Chang,Lan-ping Xu,Kai-yan Liu,Xiao-jun Huang,Xiao-hui Zhang
RED CELLS, IRON, AND ERYTHROPOIESIS
THROMBOSIS AND HEMOSTASIS
TRANSPLANTATION
Antirelapse effect of pretransplant exposure to rabbit antithymocyte globulin
Clinical Trials & Observations
Rosy Dabas,Kareem Jamani,Shahbal B. Kangarloo,Poonam Dharmani-Khan,Tyler S. Williamson,Samar Ousia,Caylib Durand,Don Morris,Douglas Mahoney,Lynn Savoie,Ahsan Chaudhry,Victor H. Jimenez-Zepeda,Faisal M. Khan,Andrew Daly,Jan Storek
GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia
Clinical Trials & Observations
Rohtesh S. Mehta,Shernan G. Holtan,Tao Wang,Michael T. Hemmer,Stephen R. Spellman,Mukta Arora,Daniel R. Couriel,Amin M. Alousi,Joseph Pidala,Hisham Abdel-Azim,Ibrahim Ahmed,Mahmoud Aljurf,Medhat Askar,Jeffery J. Auletta,Vijaya Bhatt,Christopher Bredeson,Saurabh Chhabra,Shahinaz Gadalla,James Gajewski,Robert Peter Gale,Usama Gergis,Peiman Hematti,Gerhard C. Hildebrandt,Yoshihiro Inamoto,Carrie Kitko,Pooja Khandelwal,Margaret L. MacMillan,Navneet Majhail,David I. Marks,Parinda Mehta,Taiga Nishihori,Richard F. Olsson,Attaphol Pawarode,Miguel Angel Diaz,Tim Prestidge,Muna Qayed,Hemalatha Rangarajan,Olle Ringden,Ayman Saad,Bipin N. Savani,Sachiko Seo,Ami Shah,Niketa Shah,Kirk R. Schultz,Melhem Solh,Thomas Spitzer,Jeffrey Szer,Takanori Teshima,Leo F. Verdonck,Kirsten M. Williams,Baldeep Wirk,John Wagner,Jean A. Yared,Daniel J. Weisdorf
-
Cover Image
Cover Image
COVER FIGURE
Definitive involved-site radiation therapy administered for stage IA nodular lymphocyte-predominant Hodgkin lymphoma of the right side of the neck. Lt, left; Rt, right. See the article by Pinnix et al. - PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkEditorial Board
Advertisement
Advertisement